Advertisement

International Urology and Nephrology

, Volume 52, Issue 1, pp 169–177 | Cite as

Serum levels of the endothelial glycocalyx constituents and the early failure of forearm autologous arteriovenous fistulas in end-stage renal disease patients: a prospective cohort study

  • Xianglei Kong
  • Jing Du
  • Hong Su
  • Qinlan Chen
  • Lijun Tang
  • Lei Zhang
  • Zunsong Wang
  • Liming LiangEmail author
  • Dongmei XuEmail author
Nephrology - Original Paper

Abstract

Background

The relationship between the endothelial glycocalyx constituents and the early failure of autologous arteriovenous fistulas (AVFs) in ESRD patients is still unknown.

Methods

In this prospective cohort study, 181 ESRD patients (the mean age was 53.3 ± 11.8 years, 66.3% of them were males) received forearm AVFs surgery were consecutively enrolled with a median follow-up time of 10 months. The early AVF failure was defined as a fistula that never developed adequately for dialysis use or that failed within the first 3 months of use. The serum levels of glycocalyx constituents including glypicans-1 (GPC-1), syndecans-1 (SDC-1), and hyaluronan (HA), and the indicator of endothelial activation reflected by E-selectin (ES) were determined by ELISAs.

Results

The primary patencies of AVFs were 98.3%, 96.7%, 91.7%, and 89.5% at 3, 6, 12, and 18 months, respectively. The ROC curve was plotted and demonstrated that HA, not GPC-1, SDC-1 or ES, can diagnose the AVF failure, with the cut-off value of 6.37 ng/ml, the sensitivity of 87.5%, the specificity of 46.9%, and the Youden index of 0.34, respectively. The Kaplan–Meier survival analysis demonstrated that patients with HA < 6.37 ng/mL had better patency of AVFs than patients with HA ≥ 6.37 ng/mL (log-rank test, p = 0.008). In the Cox proportional hazards analysis, after adjusting for confounders, HA (≥ 6.37 ng/mL vs. < 6.37 ng/mL) was associated with the early AVFs failure, with the OR of 5.88 (1.21–28.60).

Conclusions

This study demonstrated that HA can predict the early failure of forearm AVFs, when its serum level is more than 6.37 ng/mL.

Keywords

Endothelial glycocalyx Autologous arteriovenous fistula Patency Prognosis 

Notes

Acknowledgements

None.

Funding

This study was funded by the Clinical Medicine Innovation Program of the Science and Technology Development Programs from the Ji’nan Science and Technology Bureau (201704086), the Projects of Medical and Health Technology Development Program of Shandong Province (2017WS083), the Natural Science Foundation from Shandong Science and Technology Committee (ZR2019MH038), the National Natural Science Foundation of China (81970615), the Cultivating Fund of National Natural Science Foundation from Shandong Provincial Qianfoshan Hospital (QYPY2019NSFC1008), and the Medical Bid data Alliance of Blood Purification of Shandong Province.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki, and also under the approval of the Ethics Committee of Shandong Provincial Qianfoshan Hospital.

References

  1. 1.
    Zhang L, Wang F, Wang L et al (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379(9818):815–822CrossRefGoogle Scholar
  2. 2.
    Wang J, Zhang L, Tang SC et al (2018) Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney Int 94(1):22–25CrossRefGoogle Scholar
  3. 3.
    Nugent RA, Fathima SF, Feigl AB et al (2011) The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract 118(3):c269–c277CrossRefGoogle Scholar
  4. 4.
    Liyanage T, Ninomiya T, Jha V et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385(9981):1975–1982CrossRefGoogle Scholar
  5. 5.
    Ravani P, Palmer SC, Oliver MJ et al (2013) Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol JASN 24(3):465–473CrossRefGoogle Scholar
  6. 6.
    Ravani P, Gillespie BW, Quinn RR et al (2013) Temporal risk profile for infectious and noninfectious complications of hemodialysis access. J Am Soc Nephrol JASN 24(10):1668–1677CrossRefGoogle Scholar
  7. 7.
    Bylsma LC, Gage SM, Reichert H et al (2017) Arteriovenous fistulae for haemodialysis: a systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg 54(4):513–522CrossRefGoogle Scholar
  8. 8.
    Lee T, Roy-Chaudhury P (2009) Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis 16(5):329–338CrossRefGoogle Scholar
  9. 9.
    Roy-Chaudhury P, Arend L, Zhang J et al (2007) Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 50(5):782–790CrossRefGoogle Scholar
  10. 10.
    Stracke S, Konner K, Kostlin I et al (2002) Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 61(3):1011–1019CrossRefGoogle Scholar
  11. 11.
    Brahmbhatt A, Remuzzi A, Franzoni M et al (2016) The molecular mechanisms of hemodialysis vascular access failure. Kidney Int 89(2):303–316CrossRefGoogle Scholar
  12. 12.
    Moody WE, Edwards NC, Madhani M et al (2012) Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 223(1):86–94CrossRefGoogle Scholar
  13. 13.
    Jankovic A, Damjanovic T, Djuric Z et al (2015) Impact of vascular calcifications on arteriovenous fistula survival in hemodialysis patients: a five-year follow-up. Nephron 129(4):247–252CrossRefGoogle Scholar
  14. 14.
    Choi SJ, Yoon HE, Kim YS et al (2015) Pre-existing arterial micro-calcification predicts primary unassisted arteriovenous fistula failure in incident hemodialysis patients. Semin Dial 28(6):665–669CrossRefGoogle Scholar
  15. 15.
    Dane MJ, van den Berg BM, Lee DH et al (2015) A microscopic view on the renal endothelial glycocalyx. Am J Physiol Renal Physiol 308(9):F956–F966CrossRefGoogle Scholar
  16. 16.
    Weinbaum S, Tarbell JM, Damiano ER (2007) The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9:121–167CrossRefGoogle Scholar
  17. 17.
    Dane MJ, Khairoun M, Lee DH et al (2014) Association of kidney function with changes in the endothelial surface layer. Clin J Am Soc Nephrol 9(4):698–704CrossRefGoogle Scholar
  18. 18.
    Vlahu CA, Lemkes BA, Struijk DG et al (2012) Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 23(11):1900–1908CrossRefGoogle Scholar
  19. 19.
    Beathard GA, Arnold P, Jackson J et al (2003) Aggressive treatment of early fistula failure. Kidney Int 64(4):1487–1494CrossRefGoogle Scholar
  20. 20.
    Zhang Y, Kong X, Tang L et al (2018) Analysis of follow-up methods of vascular access and patient outcomes in hemodialysis at a tertiary care hospital in China. Ther Apheresis Dial 22(2):160–165CrossRefGoogle Scholar
  21. 21.
    Wasse H, Huang R, Naqvi N et al (2012) Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access 13(2):168–174CrossRefGoogle Scholar
  22. 22.
    Rabelink TJ, de Boer HC, van Zonneveld AJ (2010) Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 6(7):404–414CrossRefGoogle Scholar
  23. 23.
    Nieuwdorp M, van Haeften TW, Gouverneur MC et al (2006) Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55(2):480–486CrossRefGoogle Scholar
  24. 24.
    Rehm M, Bruegger D, Christ F et al (2007) Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 116(17):1896–1906CrossRefGoogle Scholar
  25. 25.
    Kong X, Han W, Su H et al (2017) The serum expression of the endothelial glycocalyx in uremic patients and healthy individuals. Int J Urol Nephrol 37(4):563–566Google Scholar
  26. 26.
    Locatelli F, Canaud B, Eckardt KU et al (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transpl 18(7):1272–1280CrossRefGoogle Scholar
  27. 27.
    Daniel JM, Penzkofer D, Teske R et al (2014) Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovasc Res 103(4):564–572CrossRefGoogle Scholar
  28. 28.
    Chen Z, Wen L, Martin M et al (2015) Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation 131(9):805–814CrossRefGoogle Scholar
  29. 29.
    Fang Y, Davies PF (2012) Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 32(4):979–987CrossRefGoogle Scholar
  30. 30.
    Lennon FE, Singleton PA (2011) Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 1(3):200–213PubMedPubMedCentralGoogle Scholar
  31. 31.
    Ramiro-Diaz J, Barajas-Espinosa A, Chi-Ahumada E et al (2010) Luminal endothelial lectins with affinity for N-acetylglucosamine determine flow-induced cardiac and vascular paracrine-dependent responses. Am J Physiol Heart Circ Physiol 299(3):H743–H751CrossRefGoogle Scholar
  32. 32.
    Mochizuki S, Vink H, Hiramatsu O et al (2003) Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol 285(2):H722–H726CrossRefGoogle Scholar
  33. 33.
    Nagy N, Freudenberger T, Melchior-Becker A et al (2010) Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation 122(22):2313–2322CrossRefGoogle Scholar
  34. 34.
    Yung S, Thomas GJ, Davies M (2000) Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro. Kidney Int 58(5):1953–1962CrossRefGoogle Scholar
  35. 35.
    Lipowsky HH, Lescanic A (2013) The effect of doxycycline on shedding of the glycocalyx due to reactive oxygen species. Microvasc Res 90:80–85CrossRefGoogle Scholar
  36. 36.
    Mulivor AW, Lipowsky HH (2004) Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 286(5):H1672–H1680CrossRefGoogle Scholar
  37. 37.
    Padberg JS, Wiesinger A, di Marco GS et al (2014) Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis 234(2):335–343CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Nephrology, Shandong Provincial Qianfoshan HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Qilu Medical CollegeShandong UniversityJinanChina
  3. 3.Center of Blood PurificationWeifang People’s HospitalWeifangChina
  4. 4.Shandong Provincial Key Laboratory for Rheumatic Disease and Translational MedicineJinanPeople’s Republic of China
  5. 5.Department of NephrologyThe First Affiliated Hospital of Shandong First Medical UniversityJinanPeople’s Republic of China
  6. 6.Nephrology Research Institute of Shandong ProvinceJinanPeople’s Republic of China

Personalised recommendations